Is NBP or DRUG more profitable?

I-Mab's return on equity of 0.00% beat Bright Minds Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A Bright Minds Biosciences N/A -20.58% -20.25%

Does the media refer more to AMPH or NBP?

In the previous week, Amphastar Pharmaceuticals had 5 more articles in the media than I-Mab. MarketBeat recorded 7 mentions for Amphastar Pharmaceuticals and 2 mentions for I-Mab. I-Mab's average media sentiment score of 0.69 beat Amphastar Pharmaceuticals' score of 0.31 indicating that I-Mab is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral I-Mab 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LBRX or NBP more profitable?

Company Net Margins Return on Equity Return on Assets LB Pharmaceuticals N/A N/A N/A I-Mab N/A N/A N/A

Does the media refer more to LBRX or NBP?

In the previous week, I-Mab had 1 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 2 mentions for I-Mab and 1 mentions for LB Pharmaceuticals. I-Mab's average media sentiment score of 0.69 beat LB Pharmaceuticals' score of 0.49 indicating that I-Mab is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral I-Mab 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NBP or SPRY?

In the previous week, I-Mab and I-Mab both had 2 articles in the media. I-Mab's average media sentiment score of 0.69 beat ARS Pharmaceuticals' score of 0.37 indicating that I-Mab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

I-Mab (NBP) Competitors

$1.80 +0.05 (+2.86%)

Closing price 04:00 PM Eastern

Extended Trading

$1.82 +0.01 (+0.83%)

As of 07:08 PM Eastern

Compare

NBP vs. DRUG, AMPH, LBRX, ESPR, and SPRY

Should you buy I-Mab stock or one of its competitors? MarketBeat compares I-Mab with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with I-Mab include Bright Minds Biosciences (DRUG), Amphastar Pharmaceuticals (AMPH), LB Pharmaceuticals (LBRX), Esperion Therapeutics (ESPR), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry.

How does I-Mab compare to Bright Minds Biosciences?

I-Mab (NASDAQ:NBP) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

I-Mab has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.53, suggesting that its stock price is 653% less volatile than the broader market.

I-Mab currently has a consensus target price of $9.00, indicating a potential upside of 400.00%. Bright Minds Biosciences has a consensus target price of $143.83, indicating a potential upside of 91.85%. Given I-Mab's higher possible upside, analysts clearly believe I-Mab is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

I-Mab's return on equity of 0.00% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Bright Minds Biosciences	N/A	-20.58%	-20.25%

Bright Minds Biosciences has lower revenue, but higher earnings than I-Mab. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	53.51	-$46.27M	-$0.36	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

38.4% of I-Mab shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Bright Minds Biosciences had 10 more articles in the media than I-Mab. MarketBeat recorded 12 mentions for Bright Minds Biosciences and 2 mentions for I-Mab. I-Mab's average media sentiment score of 0.69 beat Bright Minds Biosciences' score of 0.29 indicating that I-Mab is being referred to more favorably in the media.

Company	Overall Sentiment
I-Mab	Positive
Bright Minds Biosciences	Neutral

Summary

I-Mab beats Bright Minds Biosciences on 8 of the 14 factors compared between the two stocks.

How does I-Mab compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and I-Mab (NASDAQ:NBP) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Amphastar Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, I-Mab has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

Amphastar Pharmaceuticals has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.15	$98.09M	$1.66	11.27
I-Mab	$3.89M	53.51	-$46.27M	-$0.36	N/A

Amphastar Pharmaceuticals presently has a consensus target price of $24.00, indicating a potential upside of 28.34%. I-Mab has a consensus target price of $9.00, indicating a potential upside of 400.00%. Given I-Mab's stronger consensus rating and higher possible upside, analysts plainly believe I-Mab is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Amphastar Pharmaceuticals had 5 more articles in the media than I-Mab. MarketBeat recorded 7 mentions for Amphastar Pharmaceuticals and 2 mentions for I-Mab. I-Mab's average media sentiment score of 0.69 beat Amphastar Pharmaceuticals' score of 0.31 indicating that I-Mab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
I-Mab	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 22.1% of I-Mab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to I-Mab's net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat I-Mab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
I-Mab	N/A	N/A	N/A

Summary

Amphastar Pharmaceuticals beats I-Mab on 10 of the 16 factors compared between the two stocks.

How does I-Mab compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and I-Mab (NASDAQ:NBP) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

In the previous week, I-Mab had 1 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 2 mentions for I-Mab and 1 mentions for LB Pharmaceuticals. I-Mab's average media sentiment score of 0.69 beat LB Pharmaceuticals' score of 0.49 indicating that I-Mab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
I-Mab	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

38.4% of I-Mab shares are owned by institutional investors. 5.8% of LB Pharmaceuticals shares are owned by company insiders. Comparatively, 22.1% of I-Mab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	N/A	N/A
I-Mab	N/A	N/A	N/A

LB Pharmaceuticals presently has a consensus price target of $38.40, indicating a potential upside of 32.87%. I-Mab has a consensus price target of $9.00, indicating a potential upside of 400.00%. Given I-Mab's higher probable upside, analysts clearly believe I-Mab is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

LB Pharmaceuticals has higher earnings, but lower revenue than I-Mab. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
I-Mab	$3.89M	53.51	-$46.27M	-$0.36	N/A

Summary

I-Mab beats LB Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does I-Mab compare to Esperion Therapeutics?

I-Mab (NASDAQ:NBP) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

I-Mab has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

In the previous week, I-Mab had 2 more articles in the media than Esperion Therapeutics. MarketBeat recorded 2 mentions for I-Mab and 0 mentions for Esperion Therapeutics. Esperion Therapeutics' average media sentiment score of 1.87 beat I-Mab's score of 0.69 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
I-Mab	Positive
Esperion Therapeutics	Very Positive

I-Mab currently has a consensus target price of $9.00, indicating a potential upside of 400.00%. Esperion Therapeutics has a consensus target price of $5.54, indicating a potential upside of 77.00%. Given I-Mab's higher possible upside, analysts plainly believe I-Mab is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Esperion Therapeutics has a net margin of 0.12% compared to I-Mab's net margin of 0.00%. I-Mab's return on equity of 0.00% beat Esperion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Esperion Therapeutics	0.12%	-0.14%	0.12%

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 22.1% of I-Mab shares are owned by company insiders. Comparatively, 1.6% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Esperion Therapeutics has higher revenue and earnings than I-Mab. Esperion Therapeutics is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	53.51	-$46.27M	-$0.36	N/A
Esperion Therapeutics	$403.14M	2.00	-$22.68M	-$0.06	N/A

Summary

I-Mab and Esperion Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does I-Mab compare to ARS Pharmaceuticals?

I-Mab (NASDAQ:NBP) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

I-Mab has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. I-Mab's return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

In the previous week, I-Mab and I-Mab both had 2 articles in the media. I-Mab's average media sentiment score of 0.69 beat ARS Pharmaceuticals' score of 0.37 indicating that I-Mab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

I-Mab presently has a consensus price target of $9.00, indicating a potential upside of 400.00%. ARS Pharmaceuticals has a consensus price target of $28.60, indicating a potential upside of 215.33%. Given I-Mab's higher possible upside, equities analysts clearly believe I-Mab is more favorable than ARS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

I-Mab has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

I-Mab has higher earnings, but lower revenue than ARS Pharmaceuticals. I-Mab is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	53.51	-$46.27M	-$0.36	N/A
ARS Pharmaceuticals	$84.28M	10.69	-$171.30M	-$2.01	N/A

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

I-Mab beats ARS Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get I-Mab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBP vs. The Competition

Export

Metric	I-Mab	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$202.38M	$2.98B	$4.34B	$12.44B
Dividend Yield	N/A	15.17%	7.93%	5.33%
P/E Ratio	-5.00	12.92	18.44	22.64
Price / Sales	53.51	3,134.50	182.31	115.68
Price / Cash	N/A	28.12	53.68	55.53
Price / Book	0.90	6.32	30.95	6.72
Net Income	-$46.27M	-$40.08M	$109.80M	$337.03M
7 Day Performance	-3.74%	0.01%	-0.42%	0.09%
1 Month Performance	N/A	2.69%	N/A	-1.78%
1 Year Performance	N/A	19.13%	15.64%	33.98%

I-Mab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBP I-Mab	2.6519 of 5 stars	$1.80 +2.9%	$9.00 +400.0%	N/A	$202.38M	$3.89M	N/A	380	News Coverage Analyst Upgrade
DRUG Bright Minds Biosciences	3.2019 of 5 stars	$83.50 +0.3%	$143.83 +72.3%	+171.0%	$812.62M	N/A	N/A	N/A	Trending News Analyst Forecast Analyst Revision
AMPH Amphastar Pharmaceuticals	4.0529 of 5 stars	$18.41 +1.4%	$24.50 +33.1%	-30.4%	$811.70M	$719.89M	11.09	1,976	Analyst Forecast
LBRX LB Pharmaceuticals	1.8065 of 5 stars	$28.12 +0.4%	$38.40 +36.6%	N/A	$806.48M	N/A	N/A	16
ESPR Esperion Therapeutics	4.255 of 5 stars	$3.13 flat	$5.54 +77.0%	+199.0%	$805.76M	$403.14M	N/A	200	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBP) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

I-Mab (NBP) Competitors

NBP vs. DRUG, AMPH, LBRX, ESPR, and SPRY

How does I-Mab compare to Bright Minds Biosciences?

Summary

How does I-Mab compare to Amphastar Pharmaceuticals?

Summary

How does I-Mab compare to LB Pharmaceuticals?

Summary

How does I-Mab compare to Esperion Therapeutics?

Summary

How does I-Mab compare to ARS Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP vs. The Competition

I-Mab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

I-Mab (NBP) Competitors

NBP vs. DRUG, AMPH, LBRX, ESPR, and SPRY

How does I-Mab compare to Bright Minds Biosciences?

Which has more risk and volatility, NBP or DRUG?

Do analysts prefer NBP or DRUG?

Is NBP or DRUG more profitable?

Which has better valuation & earnings, NBP or DRUG?

Do insiders and institutionals have more ownership in NBP or DRUG?

Does the media prefer NBP or DRUG?

Summary

How does I-Mab compare to Amphastar Pharmaceuticals?

Which has more risk & volatility, AMPH or NBP?

Which has stronger valuation & earnings, AMPH or NBP?

Do analysts prefer AMPH or NBP?

Does the media refer more to AMPH or NBP?

Do insiders & institutionals believe in AMPH or NBP?

Is AMPH or NBP more profitable?

Summary

How does I-Mab compare to LB Pharmaceuticals?

Does the media refer more to LBRX or NBP?

Do insiders and institutionals believe in LBRX or NBP?

Is LBRX or NBP more profitable?

Do analysts prefer LBRX or NBP?

Which has better earnings and valuation, LBRX or NBP?

Summary

How does I-Mab compare to Esperion Therapeutics?

Which has more volatility and risk, NBP or ESPR?

Does the media prefer NBP or ESPR?

Do analysts prefer NBP or ESPR?

Is NBP or ESPR more profitable?

Do institutionals & insiders believe in NBP or ESPR?

Which has higher valuation and earnings, NBP or ESPR?

Summary

How does I-Mab compare to ARS Pharmaceuticals?

Is NBP or SPRY more profitable?

Does the media prefer NBP or SPRY?

Do analysts prefer NBP or SPRY?

Which has more risk & volatility, NBP or SPRY?

Which has preferable valuation & earnings, NBP or SPRY?

Do institutionals and insiders believe in NBP or SPRY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBP vs. The Competition

I-Mab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools